Delving into the Latest Updates on Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PRMT5(Protein arginine methyltransferase 5)	1
PDE4B(Phosphodiesterase 4B)	1

Primary purpose: To preliminarily evaluate the effectiveness of HSK44459 tablets in adult patients with moderate to severe atopic dermatitis; Secondary purpose: To evaluate the safety of HSK44459 tablets in adult patients with moderate to severe atopic dermatitis; To evaluate the pharmacokinetic (PK) characteristics of HSK44459 tablets in adult patients with moderate to severe atopic dermatitis.

Start Date-

Sponsor / Collaborator

Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

CTR20251166

/ RecruitingPhase 1

评价 HSK41959片在MTAP缺失的晚期实体瘤患者中的安全性、耐受性以及药代/药效动力学的 I 期临床研究

[Translation] A Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of HSK41959 tablets in patients with advanced solid tumors with MTAP deletion

主要目的：评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的安全性和耐受性；确定 II 期临床试验推荐剂量（RP2D）。次要目的：评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的药代动力学特征；初步评价HSK41959 片在MTAP缺失的晚期实体瘤受试者中的疗效。探索性目的：评价MTAP 缺失的晚期实体瘤受试者血液中SDMA浓度的变化。

[Translation]

Primary purpose: Evaluate the safety and tolerability of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion; determine the recommended dose (RP2D) for Phase II clinical trials. Secondary purpose: Evaluate the pharmacokinetic characteristics of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion; Preliminary evaluation of the efficacy of HSK41959 tablets in subjects with advanced solid tumors with MTAP deletion. Exploratory purpose: Evaluate the changes in SDMA concentration in the blood of subjects with advanced solid tumors with MTAP deletion.

Start Date11 Apr 2025

Sponsor / Collaborator

Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

100 Clinical Results associated with Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Login to view more data

100 Deals associated with Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data